THE OPTIMAL ANALGESIC DOSE OF ROFECOXIB: OVERVIEW OF SIX RANDOMIZED CONTROLLED TRIALS

This publication has 17 references indexed in Scilit:

• Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
  Arthritis & Rheumatism, 2000
• Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
  Arthritis & Rheumatism, 2000
• A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
  Gastroenterology, 1999
• Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial
  Clinical Therapeutics, 1999
• Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
  Clinical Pharmacology & Therapeutics, 1999
• Selective induction of cyclo‐oxygenase‐2 activity in the permanent human endothelial cell line HUV‐EC‐C: biochemical and pharmacological characterization
  British Journal of Pharmacology, 1997
• Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells
  Inflammation Research, 1997
• Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells
  Biochemical Pharmacology, 1996
• Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids
  Neuron, 1993
• Prostaglandin endoperoxide synthase: regulation of enzyme expression
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1991